Advertisement
Advertisement

RKDA

RKDA logo

Arcadia Biosciences, Inc.

1.70
USD
Sponsored
-0.02
-1.47%
Mar 25, 15:58 UTC -4
Closed
exchange

Pre-Market

1.51

-0.19
-11.12%

RKDA Earnings Reports

Positive Surprise Ratio

RKDA beat 22 of 38 last estimates.

58%

Next Report

Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.63M
/
-$0.81
Implied change from Q4 25 (Revenue/ EPS)
--
/
--
Implied change from Q1 25 (Revenue/ EPS)
+36.00%
/
-142.63%

Arcadia Biosciences, Inc. earnings per share and revenue

On Mar 18, 2026, RKDA reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.67 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 1.43 million, with a --% difference. The market reacted with a +5.77% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.81 USD, with revenue projected to reach 1.63 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
logo
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
logo
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
logo
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
logo
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
logo
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
logo
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
logo
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
logo
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
logo
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
For Q4 2025, Arcadia Biosciences, Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
The stock price moved up 5.77%, changed from $1.56 before the earnings release to $1.65 the day after.
The next earning report is scheduled for May 06, 2026.
Based on 3 analysts, Arcadia Biosciences, Inc. is expected to report EPS of -$0.81 and revenue of $1.63M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement